Antifungal susceptibility profiles of olorofim (formerly F901318), and currently available systemic antifungals against mold and yeast phases of <em>Talaromyces marneffei</em>

Antimicrob Agents Chemother. 2021 Mar 22:AAC.00256-21. doi: 10.1128/AAC.00256-21. Online ahead of print.

ABSTRACT

In vitro antifungal susceptibility of 32 clinical and environmental Talaromyces marneffei isolates recovered from southern China was performed against olorofim and 7 other systemic antifungals including: amphotericin B, 5-flucytosine, posaconazole, voriconazole, caspofungin and terbinafine using the CLSI methodology. In comparison, olorofim was the most active antifungal agent against both mold and yeast phases of all tested Talaromyces marneffei isolates, exhibiting an MIC range, MIC50, and MIC90 of 0.0005-0.002 μg/ml, 0.0005 μg/ml, and 0.0005 μg/ml, respectively.

PMID:33753341 | DOI:10.1128/AAC.00256-21